First-line tislelizumab plus chemotherapy in gastric/ gastroesophageal junction cancer: RATIONALE-305 Asian Subgroup

被引：0
|
作者：
Kato, K. [1 ]
Bai, Y. [2 ]
Shi, J. [3 ]
Lee, K. [4 ]
Wang, J. [5 ]
Pan, H. [6 ]
Rha, S. [7 ]
Zhang, R. [8 ]
Hirano, H.
Yamaguchi, K. [9 ]
Guo, Z. [10 ]
Ba, Y. [11 ]
Yang, L. [12 ]
Tsukuda, H. [13 ]
Xu, Y. [14 ]
Sheng, T. [15 ]
Yang, S. [14 ]
Li, L. [14 ]
Oh, D. [16 ]
Xu, R. [17 ]
机构：
[1] Natl Canc Ctr, Dept Head & Neck, Esophageal Med Oncol, Tokyo, Japan
[2] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[3] Linyi Canc Hosp, Linyi, Peoples R China
[4] Seoul Natl Univ, Seoul Natl Univ Bundang Hosp, Coll Med, Seongnam, South Korea
[5] Henan Canc Hosp, Zhengzhou, Peoples R China
[6] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Peoples R China
[7] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea
[8] Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China
[9] Canc Inst Hosp JFCR, Dept Gastrointestinal Med Oncol, Tokyo, Japan
[10] Fujian Canc Hosp, Fuzhou, Peoples R China
[11] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[12] Nantong Canc Hosp, Nantong, Peoples R China
[13] Izumi Municipal Hosp, Izumi, Japan
[14] BeiGene Beijing Co Ltd, Beijing, Peoples R China
[15] BeiGene Ltd, Boston, MA USA
[16] Seoul Natl Univ, Seoul Natl Univ Hosp, Canc Res Inst, Coll Med, Seoul, South Korea
[17] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, State Key Lab Oncol South China, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.07.636
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O3-4
引用
收藏
页码：S1316 / S1316
页数：1
相关论文
共 50 条
  • [1] RATIONALE 305: Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with gastric or gastroesophageal junction adenocarcinoma
    Xu, R.
    Arkenau, T.
    Bang, Y.
    Denlinger, C.
    Kato, K.
    Tabernero, J.
    Wang, J.
    Li, J.
    Castro, H.
    Moehler, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S97 - S98
  • [2] Tislelizumab plus chemotherapy (chemo) versus placebo plus chemo as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup.
    Arkenau, Hendrik-Tobias
    Tabernero, Josep
    Cruz-Correa, Marcia
    Zimina, Anastasia V.
    Poddubskaya, Elena
    Moiseenko, Fedor Vladimirovich
    Spigel, David R.
    Wyrwicz, Lucjan S.
    Disel, Umut
    Pazo Cid, Roberto
    Cubillo Gracian, Antonio
    Ales Diaz, Inmaculada
    Fornaro, Lorenzo
    Evesque, Ludovic
    Xu, Yaling
    Sheng, Tao
    Yang, Silu
    Li, Liyun
    Moehler, Markus H.
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 330 - 330
  • [3] First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305
    Moehler, Markus
    Oh, Do-Youn
    Kato, Ken
    Arkenau, Tobias
    Tabernero, Josep
    Lee, Keun-Wook
    Rha, Sun Young
    Hirano, Hidekazu
    Spigel, David
    Yamaguchi, Kensei
    Wyrwicz, Lucjan
    Disel, Umut
    Pazo-Cid, Roberto A.
    Fornaro, Lorenzo
    Xu, Yaling
    Sheng, Tao
    Yang, Silu
    Kadva, Alysha
    Cruz-Correa, Marcia
    Xu, Rui-Hua
    ADVANCES IN THERAPY, 2025, : 2248 - 2268
  • [4] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported outcomes (PRO) in the Asian subgroup of the RATIONALE-305 study
    Kato, K.
    Xu, R-H.
    Oh, D-Y.
    Bai, Y.
    Shi, J.
    Lee, K-W.
    Hirano, H.
    Xu, H.
    Sheng, T.
    Barnes, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S1456 - S1456
  • [5] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
    Xu, R-H.
    Oh, D-Y.
    Kato, K.
    Arkenau, T.
    Tabernero, J.
    Cruz-Correa, M.
    Zimina, A.
    Bai, Y.
    Shi, J.
    Lee, K-W.
    Hirano, H.
    Spigel, D. R.
    Wyrwicz, L. S.
    Cid, R. A. Pazo
    Li, L.
    Xu, Y.
    McHenry, M. B.
    Yang, S.
    Moehler, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1320 - S1321
  • [6] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
    Xu, R-H.
    Oh, D-Y.
    Kato, K.
    Arkenau, H-T.
    Tabernero, J.
    Cruz-Correa, M.
    Zimina, A. V.
    Bai, Y.
    Shi, J.
    Lee, K-W.
    Hirano, H.
    Spigel, D. R.
    Wyrwicz, L. S.
    Pazo Cid, R. A.
    Li, L.
    Xu, Y.
    McHenry, M. B.
    Yang, S.
    Moehler, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1526 - S1527
  • [7] Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
    Moehler, Markus H.
    Kato, Ken
    Arkenau, Hendrik-Tobias
    Oh, Do-Youn
    Tabernero, Josep
    Cruz-Correa, Marcia
    Wang, HongWei
    Xu, Hui
    Li, Jiang
    Yang, Silu
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 286 - 286
  • [8] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
    Qiu, Miao-Zhen
    Oh, Do-Youn
    Kato, Ken
    Arkenau, Tobias
    Tabernero, Josep
    Correa, Marcia Cruz
    Zimina, Anastasia, V
    Bai, Yuxian
    Shi, Jianhua
    Lee, Keun-Wook
    Wang, Jufeng
    Poddubskaya, Elena
    Pan, Hongming
    Rha, Sun Young
    Zhang, Ruixing
    Hirano, Hidekazu
    Spigel, David
    Yamaguchi, Kensei
    Chao, Yee
    Wyrwicz, Lucjan
    Disel, Umut
    Cid, Roberto Pazo
    Fornaro, Lorenzo
    Evesque, Ludovic
    Wang, Hongwei
    Xu, Yaling
    Li, Jiang
    Sheng, Tao
    Yang, Silu
    Li, Liyun
    Moehler, Markus
    Xu, Rui-Hua
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 385
  • [9] Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
    Xu, Jianming
    Bai, Yuxian
    Xu, Nong
    Li, Enxiao
    Wang, Buhai
    Wang, Jin
    Li, Xiang
    Wang, Xin
    Yuan, Xianglin
    CLINICAL CANCER RESEARCH, 2020, 26 (17) : 4542 - 4550
  • [10] Tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment in gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) patients with/without peritoneal or liver metastases: A post hoc analysis of RATIONALE-305 study.
    Qiu, Miaozhen
    Luo, Huiyan
    Wang, Feng-Hua
    Wang, Feng
    He, Ming-Ming
    Xu, Sheng
    Pan, Xiaoxi
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 414 - 414
12345